| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 297,344 | 312,761 | ||
| Restricted cash | 449 | 449 | ||
| Prepaid expenses and other current assets | 2,158 | 3,054 | ||
| Total current assets | 299,951 | 316,264 | ||
| Restricted cash | 2,151 | 2,151 | ||
| Property, plant and equipment, gross | 11,190 | - | ||
| Accumulated depreciation | 4,385 | - | ||
| Property, plant and equipment, net | 6,805 | 6,957 | ||
| Operating lease right-of-use assets | 7,463 | 7,773 | ||
| Other non-current assets | 184 | 186 | ||
| Total assets | 316,554 | 333,331 | ||
| Accounts payable | 5,438 | 7,713 | ||
| Accrued expenses and other current liabilities | 17,708 | 12,151 | ||
| Deferred revenue | 5,485 | 5,485 | ||
| Total current liabilities | 28,631 | 25,349 | ||
| Term loan, net | 50,852 | 41,051 | ||
| Operating lease liability, net of current portion | 16,506 | 16,808 | ||
| Other non-current liabilities | 1,576 | 1,396 | ||
| Total liabilities | 97,565 | 84,604 | ||
| Common stock, 0.00001 par value per share 700,000,000 shares authorized and 273,915,373 issued and outstanding as of september 30, 2025 and 400,000,000 shares authorized and 204,943,306 issued and outstanding as of december 31, 2024 | 3 | 3 | ||
| Additional paid-in capital | 903,578 | 900,139 | ||
| Accumulated other comprehensive loss | -1,143 | -699 | ||
| Accumulated deficit | -683,449 | -650,716 | ||
| Total stockholders' equity | 218,989 | 248,727 | ||
| Total liabilities and stockholders' equity | 316,554 | 333,331 | ||
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)